- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
89Zr-DFO-girentuximab May Improve Identification, Risk Stratification of Renal Tumors
May 2nd 2023, 6:00pm
American Urological Association Annual Meeting
Findings from the phase 3 ZIRCON trial showed that imaging with 89Zr-DFO-girentuximab could improve the identification and risk stratification of patients with renal tumors.
Apalutamide Plus ADT Improves PSA PFS in Biochemically Relapsed Prostate Cancer
May 2nd 2023, 5:00pm
American Urological Association Annual Meeting
Apalutamide plus androgen deprivation therapy with or without abiraterone acetate and prednisone improved prostate-specific antigen progression-free survival in patients with biochemically relapsed prostate cancer, according to long-term follow-up data from the phase 3 PRESTO trial.
Dr Daneschmand on Data From SunRISe-1 With TAR-200 and Cetrelimab in BCG-Unresponsive NMIBC
May 1st 2023, 4:18pm
American Urological Association Annual Meeting
Sia Daneshmand MD, discusses preliminary results from the phase 2 SunRISe-1 trial (NCT04640623) in patients with non–muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guérin.
Dr Saad on PSA Response and Time to PSA Progression With Abiraterone Acetate and Olaparib in mCRPC
May 1st 2023, 4:15pm
American Urological Association Annual Meeting
Fred Saad, MD, FRCS, discusses prostate-specific antigen (PSA) response and time to PSA progression with the combination of abiraterone acetate and olaparib in patients with metastatic castration-resistant prostate cancer.
Pembrolizumab Monotherapy Demonstrates Clinical Efficacy in High-risk NMIBC
May 1st 2023, 1:40pm
American Urological Association Annual Meeting
Treatment with pembrolizumab monotherapy resulted in stable long-term disease-free survival rates in patients with Bacillus Calmette-Guérin–unresponsive, high-risk non–muscle-invasive bladder cancer.
TAR-200 Produces High CR Rates, Tolerability in BCG-unresponsive NMIBC
May 1st 2023, 1:24pm
American Urological Association Annual Meeting
Treatment with TAR-200 produced complete responses and was well tolerated in patients with Bacillus Calmette-Guérin–unresponsive, high-risk non–muscle-invasive bladder cancer, according to preliminary data from the phase 2b SunRISe-1 trial.
Nivolumab Maintains DFS Benefit in MIUC and MIBC After Radical Surgery
May 1st 2023, 12:56pm
American Urological Association Annual Meeting
Nivolumab following radical surgery continued to display a benefit in disease-free survival in patients with muscle-invasive urothelial carcinoma and muscle-invasive bladder cancer.
Sintilimab Plus Axitinib Has Clinical Efficacy in Advanced FH-Deficient RCC
April 30th 2023, 4:43pm
American Urological Association Annual Meeting
Treatment with sintilimab in combination with axitinib resulted in tumor shrinkage with tolerable adverse effects in patients with advanced fumarate hydratase–deficient renal cell carcinoma.
Complications Following Partial Nephrectomy Associated With Particular Comorbidities in RCC
April 30th 2023, 1:57pm
American Urological Association Annual Meeting
Specific comorbidities were linked with complications following partial nephrectomy, compared with radical nephrectomy, in patients with T1b to T2 renal cell carcinoma.
Hypertension Linked With Worse Outcomes for Patients With Upper Tract Urothelial Cancer Undergoing Nephroureterectomy
April 30th 2023, 1:45pm
American Urological Association Annual Meeting
Hypertension was found to be an independent risk factor for worse survival outcomes in patients with upper tract urothelial cancer undergoing radical nephroureterectomy.
High BMI Associated With Longer OS in Patients With RCC Undergoing Nephrectomy
April 30th 2023, 1:12pm
American Urological Association Annual Meeting
A high body mass index was linked with improved overall survival in patients with renal cell carcinoma undergoing radical nephrectomy.
Dr Lowentritt on PSA Response and Time to Castration Resistance in mCSPC
April 29th 2023, 9:13pm
American Urological Association Annual Meeting
Benjamin H. Lowentritt, MD, FACS, discusses prostate-specific antigen response and time to castration resistance in patients with metastatic castration-sensitive prostate cancer started on apalutamide, enzalutamide, or abiraterone acetate.
Dr Li on the Use of CG0070 Plus Pembrolizumab in BCG-Unresponsive Non–muscle Invasive Bladder Cancer
April 29th 2023, 8:10pm
American Urological Association Annual Meeting
Roger Li, MD, discusses phase 2 data with the combination of CG0070 and pembrolizumab in patients with non–muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guérin.
Enzalutamide With or Without Leuprolide Offers MFS Benefit Vs Leuprolide Alone in nmHSPC With High-risk BCR
April 29th 2023, 7:31pm
American Urological Association Annual Meeting
Treatment with the androgen receptor inhibitor enzalutamide plus leuprolide led to a significant reduction in the risk of metastasis or death compared with placebo plus leuprolide in patients with nonmetastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence.
Apalutamide Demonstrates Robust Real-World Effectiveness in mCSPC
April 29th 2023, 6:53pm
American Urological Association Annual Meeting
Patients with metastatic castration-sensitive prostate cancer treated with the androgen receptor–signaling inhibitor apalutamide achieved prostate-specific antigen responses that trended higher and rates of progression to castration resistance that trended lower than those receiving enzalutamide or abiraterone acetate/
Darolutamide Plus ADT/Docetaxel Produces Durable PSA Responses in mHSPC
April 29th 2023, 5:47pm
American Urological Association Annual Meeting
A post-hoc analysis of the phase 3 ARASENS trial demonstrated that the addition of darolutamide to androgen deprivation therapy and docetaxel produced deep and durable prostate-specific antigen responses in patients with metastatic hormone-sensitive prostate cancer.
Darolutamide Plus ADT Elicits OS Benefit in North American Patients With mHSPC
April 29th 2023, 5:12pm
American Urological Association Annual Meeting
A subgroup analysis of the phase 3 ARASENS trial showed that darolutamide plus androgen deprivation therapy elicited an overall survival benefit in North American patients with metastatic hormone-sensitive prostate cancer.
Phase 2 Data Show Clinical Activity With CG0070 Plus Pembrolizumab in NMIBC
April 29th 2023, 4:40pm
American Urological Association Annual Meeting
Cretostimogene grenadenorepvec in combination with pembrolizumab produced high complete response rates with a tolerable safety profile in patients with Bacillus Calmette-Guérin–unresponsive non–muscle invasive bladder cancer.
Darolutamide Associated With Lower Rates of Treatment Discontinuation and Disease Progression in nmCRPC
April 29th 2023, 3:39pm
American Urological Association Annual Meeting
Treatment with darolutamide was associated with lower rates of discontinuation and progression to metastatic disease compared with enzalutamide and apalutamide in patients with nonmetastatic castration-resistant prostate cancer.
Long-Term JAVELIN Bladder 100 Data Support Avelumab Maintenance in Advanced Urothelial Carcinoma
April 28th 2023, 10:55pm
American Urological Association Annual Meeting
First-line avelumab maintenance therapy prolonged survival in patients with advanced urothelial carcinoma, regardless of response to first-line chemotherapy, according to findings from an exploratory subgroup analysis of the phase 3 JAVELIN Bladder 100 trial.